Status:
UNKNOWN
Description of the Short-term Effects of KAFTRIO® by Continuous Monitoring With the PHEAL-CR-K Application in Real Life in Patients With Cystic Fibrosis Eligible for KAFTRIO® Treatment
Lead Sponsor:
Hopital Foch
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a prospective, open-label, multicenter study (1 year) with 50 patients with cystic fibrosis for whom treatment with KAFTRIO® is prescribed.Cystic fibrosis is a rare autosomal recessive heredit...
Eligibility Criteria
Inclusion
- Patients aged 18 and over
- Patients with Cystic Fibrosis eligible for KAFTRIO®
- Patients for which KAFTRIO® treatment is prescribed, including patients previously treated with other CFTR modulators (ORKAMBI®, KALYDECO®, SYMKEVI®)
- Patients who signed the informed consent form
- Patients affiliated to a health insurance plan
- Patients equipped with a smartphone and having a Wifi connection at home
Exclusion
- Pregnant or breastfeeding women
- Patient who does not speak or understand French
- Patient deprived of liberty or under guardianship
Key Trial Info
Start Date :
March 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05295524
Start Date
March 14 2022
End Date
March 1 2023
Last Update
August 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Grenet Dominique
Suresnes, France